Fate Therapeutics, Inc.

As of August 25, 2025, Fate Therapeutics, Inc. has shifted to a bearish trend with weak strength indicators, showing a 1-year return of -74.23% and a 5-year return of -97.45% compared to the S&P 500's positive performance.

As of June 20, 2025, the market trend for Fate Therapeutics, Inc. has shifted to mildly bearish, supported by daily moving averages and mixed monthly indicators, despite some bullish signals on the weekly MACD.

As of March 2022, the management team of Fate Therapeutics, Inc. includes Dr. William Rastetter (Independent Chairman), Mr. John Wolchko (CEO), and several independent directors, including Dr. John Mendlein and Dr. Shefali Agarwal.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders. As of March 2025, it has a market cap of $137.56 million, with net sales of $2 million and a net loss of $38 million.

As of Jun 18, Fate Therapeutics, Inc. has a market capitalization of 137.56 million, classifying it as a Micro Cap company, with net sales of 13.33 million and a net profit of -175.88 million over the latest four quarters. The company reported shareholder's funds of 318.73 million and total assets of 440.69 million as of Dec 24.